Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

To compare real world characteristics and efficacy of Peginterferon Beta-1A with other platform injectable therapies in patients with multiple sclerosis

Trial Profile

To compare real world characteristics and efficacy of Peginterferon Beta-1A with other platform injectable therapies in patients with multiple sclerosis

Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Nov 2018

At a glance

  • Drugs Peginterferon beta-1a (Primary) ; Glatiramer acetate; Interferon beta-1a; Interferon beta-1a; Interferon beta-1b
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Nov 2018 Results assessing the relapse rates (n=1864) and relapse-related hospitalisation (n=1724) in RRMS patients treated with peginterferon beta-1a and other injectable therapies, presented at the 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
    • 19 Oct 2017 New trial record
    • 12 Oct 2017 Results presented at the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top